K-232 clinical pharmacology study

K-232 clinical pharmacology study in healthy adult males

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080225220

Enrollment

Registered

2020-06-08

Start date

2020-06-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy males

Interventions

investigational material(s) Generic name etc : K-232 INN of investigational material : - Therapeutic category code : 131 Agents for ophthalmic use Dosage and Administration for Investigational materia

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: healthy males

Exclusion criteria

Exclusion criteria: 1.Subjects who having a history of drug allergy 2.Subjects thought to wear contact lenses during this trial etc.

Design outcomes

Primary

Measure	Time frame
safety pharmacokinetics Pharmacokinetics: Plasma drug concentration of Ripasudil, its metabolites and Brimonidine Safety: Incidence of adverse event and adverse drug reaction	—

Secondary

Measure	Time frame
safety other Safety :Change from baseline in ophthalmologic examination, physiological examination, clinical examination Other :Change from baseline in intraocular pressure	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026